Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting
12:12pm, Monday, 18'th Oct 2021
The FDA has greenlit Roche Holdings AG's (OTC: RHHBY) Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with the expression of the PD-L1 biomarker c
SANTA CLARA, Calif., Oct. 18, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with Ibex Medical Analytics, a global leader in artificial intel
Roche family shareholders will maintain stability - vice chairman
05:28am, Sunday, 17'th Oct 2021
The head of Roche's controlling group of shareholders is "very confident" stability can be maintained at the pharmaceuticals company after the next generation of heirs joined the family pool of invest
3 COVID-19 Pill Stocks to Watch
06:10am, Saturday, 16'th Oct 2021
These big drugmakers could soon compete against each other with oral COVID-19 therapies.
FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
12:30pm, Friday, 15'th Oct 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentr
Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care
01:00am, Friday, 15'th Oct 2021
Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for patholo
Basel, 14 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new longer-term efficacy and safety data for ENSPRYNG® (satralizumab). The data show ENSPRYNG has a favourable benefit:ri
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new longer-term efficacy and safety data for Enspryng™ (satralizuma
Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disa
Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status
10:58am, Tuesday, 12'th Oct 2021
Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.
Genentech's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer's Disease
04:48pm, Friday, 08'th Oct 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that gantenerumab, an anti-amyloid beta antibody developed for subcut
Roche's Alzheimer's Candidate Secures FDA Breakthrough Designation
03:37pm, Friday, 08'th Oct 2021
Roche Holdings AG's (OTC: RHHBY) gantenerumab antibody received breakthrough therapy designation from the FDA for Alzheimer's disease. Gantenerumab is designed to neutralize beta-amyloid plaques se
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that gantenerumab, an anti-amyloid beta antibody developed for subcut
Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021
01:00am, Tuesday, 05'th Oct 2021
Basel, 5 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) and ENSPRYNG® (satralizumab) data will be presented at the 37th Congress of the European Co
Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail
07:15am, Thursday, 30'th Sep 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Roche Holdings AG (OTC: RHHBY) announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitali
